Ad is loading...
IDYA
Price
$26.64
Change
-$2.83 (-9.60%)
Updated
Nov 15 closing price
135 days until earnings call
KALV
Price
$9.49
Change
-$0.31 (-3.16%)
Updated
Nov 15 closing price
18 days until earnings call
Ad is loading...

IDYA vs KALV

Header iconIDYA vs KALV Comparison
Open Charts IDYA vs KALVBanner chart's image
IDEAYA Biosciences
Price$26.64
Change-$2.83 (-9.60%)
Volume$1.2M
CapitalizationN/A
KalVista Pharmaceuticals
Price$9.49
Change-$0.31 (-3.16%)
Volume$816.28K
CapitalizationN/A
IDYA vs KALV Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
IDYA vs. KALV commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongSell and KALV is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (IDYA: $26.64 vs. KALV: $9.49)
Brand notoriety: IDYA and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 146% vs. KALV: 198%
Market capitalization -- IDYA: $2.3B vs. KALV: $467.05M
IDYA [@Biotechnology] is valued at $2.3B. KALV’s [@Biotechnology] market capitalization is $467.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 2 TA indicator(s) are bullish while KALV’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 2 bullish, 5 bearish.
  • KALV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KALV is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -14.83% price change this week, while KALV (@Biotechnology) price change was -16.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

IDYA is expected to report earnings on Apr 01, 2025.

KALV is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.3B) has a higher market cap than KALV($467M). KALV YTD gains are higher at: -22.531 vs. IDYA (-25.126). KALV has higher annual earnings (EBITDA): -131.18M vs. IDYA (-187.16M). IDYA has more cash in the bank: 702M vs. KALV (210M). IDYA has less debt than KALV: IDYA (1.87M) vs KALV (7.32M). IDYA has higher revenues than KALV: IDYA (12M) vs KALV (0).
IDYAKALVIDYA / KALV
Capitalization2.3B467M493%
EBITDA-187.16M-131.18M143%
Gain YTD-25.126-22.531112%
P/E RatioN/AN/A-
Revenue12M0-
Total Cash702M210M334%
Total Debt1.87M7.32M26%
FUNDAMENTALS RATINGS
KALV: Fundamental Ratings
KALV
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYAKALV
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
N/A
View a ticker or compare two or three
Ad is loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNUX22.48-0.15
-0.66%
MFS Equity Income R4
MITCX37.33-0.46
-1.22%
MFS Massachusetts Investors Tr C
RTSSX43.28-0.59
-1.34%
Russell Inv Tax-Managed US Mid&Sm Cap S
SPFFX27.01-0.39
-1.42%
Sphere 500 Climate Fund
BSGIX17.19-0.27
-1.55%
Baird Small/Mid Cap Growth Institutional

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-9.60%
GRI - IDYA
54%
Loosely correlated
-19.57%
PLRX - IDYA
48%
Loosely correlated
-3.27%
INAB - IDYA
47%
Loosely correlated
-0.21%
ALEC - IDYA
46%
Loosely correlated
-17.21%
RCKT - IDYA
45%
Loosely correlated
-5.67%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with FATE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-3.16%
FATE - KALV
45%
Loosely correlated
-2.88%
INZY - KALV
44%
Loosely correlated
-8.89%
PLRX - KALV
42%
Loosely correlated
-3.27%
ALLO - KALV
41%
Loosely correlated
-7.72%
IDYA - KALV
41%
Loosely correlated
-9.60%
More